CureDM Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
3
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2M
CureDM General Information
Description
Operator of a biopharmaceutical company intended to develop new therapies that may prevent, ameliorate or reverse diabetes. The company has discovered and is developing a novel human peptide associated with the regeneration of insulin-producing islets within the pancreas, thereby enabling customers the discontinuation of insulin.
Contact Information
Website
www.curedm.comCorporate Office
- 1201 North Market Street
- Suite 701
- Wilmington, DE 19801
- United States
Corporate Office
- 1201 North Market Street
- Suite 701
- Wilmington, DE 19801
- United States
CureDM Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 12-Feb-2018 | $2M | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series C2) | 10-Aug-2009 | Completed | Generating Revenue | |||
| 4. Debt - General | 28-Jan-2009 | Completed | Generating Revenue | |||
| 3. Debt - General | 27-Feb-2008 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 30-Nov-2006 | $2.5M | $2.79M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 22-Nov-2005 | $290K | $290K | Completed | Startup |
CureDM Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C2 | ||||||||
| Series C1 | ||||||||
| Series B | 2,469,711 | $0.001000 | $1.24 | $1.24 | 1x | $0.78 | 13.55% | |
| Series A | 1,463,483 | $0.001000 | $0.5 | $0.5 | 1x | $0.48 | 5.22% |
CureDM Patents
CureDM Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20110082080-A1 | Compositions and methods of using the human proislet peptide receptor | Inactive | 12-Oct-2007 | ||
| WO-2009049222-A1 | Compositions and methods of using the human proislet peptide receptor | Inactive | 12-Oct-2007 | ||
| JP-2014028825-A | Composition and method of using pancreatic islet formation promoting peptide and analog thereof | Active | 30-Aug-2007 | ||
| AU-2008292913-A1 | Compositions and methods of using proislet peptides and analogs thereof | Active | 30-Aug-2007 | ||
| AU-2008292913-B2 | Compositions and methods of using proislet peptides and analogs thereof | Inactive | 30-Aug-2007 | C07K14/47 |
CureDM Signals
CureDM Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Calvert Research | Venture Capital | Minority | ||
| Scientific Health Development | Venture Capital | Minority |
CureDM FAQs
-
When was CureDM founded?
CureDM was founded in 2004.
-
Where is CureDM headquartered?
CureDM is headquartered in Wilmington, DE.
-
What is the size of CureDM?
CureDM has 3 total employees.
-
What industry is CureDM in?
CureDM’s primary industry is Drug Discovery.
-
Is CureDM a private or public company?
CureDM is a Private company.
-
What is the current valuation of CureDM?
The current valuation of CureDM is .
-
What is CureDM’s current revenue?
The current revenue for CureDM is .
-
How much funding has CureDM raised over time?
CureDM has raised $6.36M.
-
Who are CureDM’s investors?
Calvert Research and Scientific Health Development have invested in CureDM.
-
When was CureDM acquired?
CureDM was acquired on 12-Feb-2018.
-
Who acquired CureDM?
CureDM was acquired by Boston Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process